Literature DB >> 18258927

Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.

Georg Feldmann1, Anirban Maitra.   

Abstract

Pancreatic ductal adenocarcinoma (ie, pancreatic cancer) is among the most devastating of human malignancies. It is commonly diagnosed at advanced, already metastatic, and, hence, incurable stages. Despite extensive research efforts in recent decades, pancreatic cancer remains resistant to almost all clinically available therapy regimens. Recent advances in our understanding of the underlying pathophysiology and molecular biology have opened up avenues for the development of novel diagnostic and therapeutic strategies, some of which have shown highly promising preclinical results and are currently being translated into clinical application. Here in we present a review of recent literature on the molecular genetics of pancreatic cancer and emphasize clinical implications for the development of novel diagnostic and therapeutic approaches.

Entities:  

Mesh:

Year:  2008        PMID: 18258927      PMCID: PMC2259464          DOI: 10.2353/jmoldx.2008.070115

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  135 in total

1.  The Notch signaling pathway is related to neurovascular progression of pancreatic cancer.

Authors:  Peter Büchler; Amiq Gazdhar; Mario Schubert; Nathalia Giese; Howard A Reber; Oscar J Hines; Thomas Giese; Güralp O Ceyhan; Michael Müller; Markus W Büchler; Helmut Friess
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

2.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

3.  Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice.

Authors:  Kenji Kimura; Kennichi Satoh; Atsushi Kanno; Shin Hamada; Morihisa Hirota; Mareyuki Endoh; Atsushi Masamune; Tooru Shimosegawa
Journal:  Cancer Sci       Date:  2007-02       Impact factor: 6.716

4.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

5.  Consistent chromosome abnormalities in adenocarcinoma of the pancreas.

Authors:  C A Griffin; R H Hruban; L A Morsberger; T Ellingham; P P Long; E M Jaffee; K M Hauda; S K Bohlander; C J Yeo
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

6.  High-resolution characterization of the pancreatic adenocarcinoma genome.

Authors:  Andrew J Aguirre; Cameron Brennan; Gerald Bailey; Raktim Sinha; Bin Feng; Christopher Leo; Yunyu Zhang; Jean Zhang; Joseph D Gans; Nabeel Bardeesy; Craig Cauwels; Carlos Cordon-Cardo; Mark S Redston; Ronald A DePinho; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-15       Impact factor: 11.205

7.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 8.  Molecular pathogenesis of Fanconi anemia: recent progress.

Authors:  Toshiyasu Taniguchi; Alan D D'Andrea
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

Review 9.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

Authors:  L R Kelland
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

10.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays.

Authors:  D Pinkel; R Segraves; D Sudar; S Clark; I Poole; D Kowbel; C Collins; W L Kuo; C Chen; Y Zhai; S H Dairkee; B M Ljung; J W Gray; D G Albertson
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

View more
  26 in total

1.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

2.  Development of a VX2 pancreatic cancer model in rabbits: a pilot study.

Authors:  Aaron C Eifler; Robert J Lewandowski; Sumeet Virmani; Johnathan C Chung; Dingxin Wang; Richard L Tang; Barbara Szolc-Kowalska; Gayle E Woloschak; Guang-Yu Yang; Robert K Ryu; Riad Salem; Andrew C Larson; Eric Cheon; Matthew Strouch; David J Bentrem; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2009-06-28       Impact factor: 3.464

Review 3.  The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.

Authors:  Nardin Samuel; Thomas J Hudson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-12-20       Impact factor: 46.802

4.  Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

Authors:  Georg Feldmann; Anjali Mishra; Savita Bisht; Collins Karikari; Ignacio Garrido-Laguna; Zeshaan Rasheed; Niki A Ottenhof; Tikva Dadon; Hector Alvarez; Volker Fendrich; N V Rajeshkumar; William Matsui; Peter Brossart; Manuel Hidalgo; Rajat Bannerji; Anirban Maitra; Barry D Nelkin
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

5.  Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.

Authors:  Georg Feldmann; Collins Karikari; Marco dal Molin; Stephanie Duringer; Petra Volkmann; Detlef K Bartsch; Savita Bisht; Jan-Bart Koorstra; Peter Brossart; Anirban Maitra; Volker Fendrich
Journal:  Cancer Biol Ther       Date:  2011-06-01       Impact factor: 4.742

6.  Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.

Authors:  Ji Kon Ryu; Seung-Mo Hong; Collins A Karikari; Ralph H Hruban; Michael G Goggins; Anirban Maitra
Journal:  Pancreatology       Date:  2010-03-20       Impact factor: 3.996

Review 7.  [Pancreatic carcinoma].

Authors:  M P Lutz; S Pourebrahim
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

8.  Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway.

Authors:  Chenghai Li; Zhengfeng Yang; Chunyan Zhai; Wenwei Qiu; Dali Li; Zhengfang Yi; Lei Wang; Jie Tang; Min Qian; Jian Luo; Mingyao Liu
Journal:  Mol Cancer       Date:  2010-04-06       Impact factor: 27.401

9.  Numb regulates acinar cell dedifferentiation and survival during pancreatic damage and acinar-to-ductal metaplasia.

Authors:  Renee L Greer; Binnaz K Staley; Angela Liou; Matthias Hebrok
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

10.  Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.

Authors:  Lars Plassmeier; Richard Knoop; Jens Waldmann; Rebecca Kesselring; Malte Buchholz; Stefan Fichtner-Feigl; Detlef K Bartsch; Volker Fendrich
Journal:  Langenbecks Arch Surg       Date:  2013-08-30       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.